IRVING, Texas, March 27,
2014 /PRNewswire/ -- RBC Life Sciences, Inc. (OTCQB: RBCL), a
provider of proprietary nutritional supplements, and wound care and
pain management products, today reported consolidated net sales of
$25.5 million for the year ended
December 31, 2013, a 1% increase over
2012 consolidated net sales of $25.2
million. For the year ended December 31, 2013, the Company reported a net
loss of $500,000, or $0.23 per diluted share, compared to a net loss
of $361,000, or $0.16 per diluted share, during 2012.
"During 2013, sales of our Nutritional Products increased by
$0.2 million, primarily as a result
of increased sales to our international licensees. Our
Medical Products sales increased by $0.1
million, despite a significant decrease in sales to our
largest customer in this segment while it seeks to settle a
reimbursement dispute with Medicare," said RBC Life Sciences CEO,
Clinton H. Howard. "Although
our net loss in 2013 increased compared to 2012, our 2012 earnings
included a benefit related to a casualty gain on the replacement of
the roof of our facility in Irving, Texas. This casualty gain
provided a pre-tax benefit of $0.4
million, which did not recur in 2013. The Company made
significant progress during 2013 by reducing expenses by
$0.9 million. The benefit from
reduced expenses was partially offset by lower gross margins which
resulted from a shift in sales mix toward lower margin licensee
sales, and higher product costs incurred in both the licensee
channel and Medical Products segment."
Mr. Howard continued, "While we were disappointed in our
financial results, we have commenced a number of initiatives to
drive our top-line performance, including the opening of new
markets for our Nutritional Products in Australia, Hong
Kong and Malaysia. During 2013, we separated the
responsibilities for sales and marketing, and augmented our team by
hiring Bart Dangerfield as our Vice
President - Marketing. Bart is an experienced marketing
executive whose resume includes driving sales growth at other
multi-level marketing companies. We are also investing in new
tools and training materials to help our Associates become even
more successful. We expect these investments to result in a
significant improvement in our sales and profitability in
2014."
About RBC Life Sciences
Through wholly-owned subsidiaries, RBC Life Sciences
develops, markets and distributes high-quality nutritional
supplements under the RBC Life brand to a growing population of
consumers seeking a healthy lifestyle and an opportunity to
increase their long term family income. Through its wholly-owned
subsidiary, MPM Medical, the Company also develops and markets to
health care professionals in the United
States proprietary prescription and nonprescription products
for advanced wound care and pain management. All products are
tested for quality assurance in-house, and by outside independent
laboratories, to comply with regulations in the U.S. and in more
than 30 countries in which the products are distributed. For more
information, visit the company's website at
www.rbclifesciences.com.
The statements above, other than statements of historical
fact, that express a belief, expectation or intention may be
forward-looking statements within the meaning of the federal
securities laws. Actual events will be dependent upon a number of
factors and risks including, but not limited to, changes in plans
by the Company's management, delays or problems in production,
changes in the regulatory process, changes in market trends, and a
number of other factors and risks described from time to time in
the Company's filings with the Securities and Exchange
Commission. Although we believe that the expectations
reflected in these forward-looking statements are reasonable, we
can give no assurance that such expectations will prove to have
been correct. Further, we specifically disclaim any duty to
update any of the information set forth in this press release,
including any forward-looking statements. Forward looking
statements are made based on management's current expectations and
beliefs concerning future events and, therefore, involve a number
of assumptions, risks and uncertainties. Management cautions
that forward-looking statements are not guarantees, and our actual
results could differ materially from those expressed or implied in
the forward-looking statements.
RBC Life Sciences,
Inc.
Summary Results of
Operations
(in thousands, except
per share data)
(unaudited)
|
|
|
Years Ended
December 31,
|
|
2013
|
|
2012
|
Net sales
|
$
|
25,471
|
|
$
|
25,160
|
Gross
profit
|
12,012
|
|
12,632
|
Operating income
(loss)
|
(625)
|
|
(464)
|
Loss before income
taxes
|
(736)
|
|
(590)
|
Provision (benefit)
for income taxes
|
(236)
|
|
(229)
|
Net loss
|
(500)
|
|
(361)
|
|
|
|
|
Loss per share -
basic
|
$(0.23)
|
|
$(0.16)
|
Loss per share -
diluted
|
(0.23)
|
|
(0.16)
|
|
|
|
|
Weighted average
shares outstanding - basic
|
2,219
|
|
2,223
|
Weighted average
shares outstanding - diluted
|
2,219
|
|
2,223
|
RBC Life Sciences,
Inc.
Condensed
Consolidated Balance Sheets
(in
thousands)
(unaudited)
|
|
|
Years Ended
December 31,
|
|
2013
|
|
2012
|
Assets
|
|
|
|
Cash and cash
equivalents
|
$
|
3,746
|
|
$
|
3,896
|
Inventories
|
5,142
|
|
5,085
|
Other current
assets
|
2,130
|
|
2,173
|
Total current
assets
|
11,018
|
|
11,154
|
Other
assets
|
6,516
|
|
6,860
|
Total
assets
|
$
|
17,534
|
|
$
|
18,014
|
|
|
|
|
Liabilities and
shareholders' equity
|
|
|
|
Accounts payable and
accrued liabilities
|
$
|
2,765
|
|
$
|
2,606
|
Deferred
revenue
|
3,678
|
|
3,231
|
Other current
liabilities
|
212
|
|
197
|
Total current
liabilities
|
6,655
|
|
6,034
|
Other
liabilities
|
1,865
|
|
2,465
|
Shareholders'
equity
|
9,014
|
|
9,515
|
Total liabilities and
shareholders' equity
|
$
|
17,534
|
|
$
|
18,014
|
For Further Information:
Richard S. Jablonski, VP-Finance and
CFO
Tel: 972-893-4000
rick.jablonski@rbclifesciences.com
SOURCE RBC Life Sciences, Inc.